Literature DB >> 7542032

Sequences within the coding regions of clotting factor VIII and CFTR block transcriptional elongation.

D D Koeberl1, C L Halbert, A Krumm, A D Miller.   

Abstract

The clotting factor VIII (FVIII) and cystic fibrosis transmembrane conductance regulator (CFTR) cDNAs have dramatically reduced levels of expression compared to clotting factor IX (FIX) and other cDNAs (100 and 1,000-fold lower, respectively), when produced in cells by using an expression vector. Part of the inhibitory signal in the FVIII cDNA has been localized to a 1.2-kb inhibitory sequence (FVIII INS), which decreased steady-state RNA levels from a retroviral vector by 30- to 100-fold. An analysis of RNA degradation indicated that the FVIII INS vector RNA is relatively stable. Nuclear run-on experiments with the FVIII INS vector demonstrated a low signal for FVIII, in contrast to the high signal for a FIX vector. The low signal for FVIII INS was not due to a decrease in transcriptional initiation. Thus, FVIII expression is reduced through a block to transcriptional elongation, as has been found in c-myc and other genes. We show that the inhibitory effect of FVIII INS is orientation dependent with regard to the promoter. In addition, the inhibitory effect is position dependent, because expression of FVIII INS sequence increased when it was moved 1 kb further from the promoter in a retroviral vector. Similar results were observed by using a retroviral vector for expression of the CFTR cDNA. The CFTR retroviral vector produced 1,000-fold decreased steady-state RNA levels, compared to the parent vector. Nuclear run-on analysis with the CFTR vector revealed a block to transcriptional elongation within the CFTR cDNA. The presence of blocks to transcriptional elongation within the FVIII and CFTR cDNAs complicates efforts to produce high levels of these proteins for therapeutic purposes and to develop high-titer retroviral expression vectors for human gene therapy.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7542032     DOI: 10.1089/hum.1995.6.4-469

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  9 in total

1.  Advancements in gene transfer-based therapy for hemophilia A.

Authors:  Christopher B Doering; H Trent Spencer
Journal:  Expert Rev Hematol       Date:  2009-12       Impact factor: 2.929

2.  Functional factor VIII made with von Willebrand factor at high levels in transgenic milk.

Authors:  S W Pipe; H Miao; S P Butler; J Calcaterra; W H Velander
Journal:  J Thromb Haemost       Date:  2011-11       Impact factor: 5.824

3.  The human clotting factor VIII cDNA contains an autonomously replicating sequence consensus- and matrix attachment region-like sequence that binds a nuclear factor, represses heterologous gene expression, and mediates the transcriptional effects of sodium butyrate.

Authors:  F J Fallaux; R C Hoeben; S J Cramer; D J van den Wollenberg; E Briët; H van Ormondt; A J van Der Eb
Journal:  Mol Cell Biol       Date:  1996-08       Impact factor: 4.272

4.  Expression of human blood clotting factor VIII in the mammary gland of transgenic sheep.

Authors:  H Niemann; R Halter; J W Carnwath; D Herrmann; E Lemme; D Paul
Journal:  Transgenic Res       Date:  1999-06       Impact factor: 2.788

5.  Prospects for the use of artificial chromosomes and minichromosome-like episomes in gene therapy.

Authors:  Sara Pérez-Luz; Javier Díaz-Nido
Journal:  J Biomed Biotechnol       Date:  2010-08-24

6.  Temporal and spatial expression of biologically active human factor VIII in the milk of transgenic mice driven by mammary-specific bovine alpha-lactalbumin regulation sequences.

Authors:  Chuan-Mu Chen; Chih-Hong Wang; Shinn-Chih Wu; Chih-Cheng Lin; Shwu-Hwa Lin; Winston T K Cheng
Journal:  Transgenic Res       Date:  2002-06       Impact factor: 2.788

7.  Generation of an optimized lentiviral vector encoding a high-expression factor VIII transgene for gene therapy of hemophilia A.

Authors:  J M Johnston; G Denning; C B Doering; H T Spencer
Journal:  Gene Ther       Date:  2012-09-20       Impact factor: 5.250

8.  Preclinical assessment of an optimized AAV-FVIII vector in mice and non-human primates for the treatment of hemophilia A.

Authors:  Liron Elkouby; Sean M Armour; Raffaella Toso; Marti DiPietro; Robert J Davidson; Giang N Nguyen; Mallory Willet; Stephanie Kutza; Joseph Silverberg; Jennifer Frick; Marco Crosariol; Yuhuan Wang; Chuansong Wang; Katherine A High; Denise E Sabatino; Xavier M Anguela
Journal:  Mol Ther Methods Clin Dev       Date:  2021-11-24       Impact factor: 6.698

9.  Blood Clotting Factor VIII: From Evolution to Therapy.

Authors:  N A Orlova; S V Kovnir; I I Vorobiev; A G Gabibov; A I Vorobiev
Journal:  Acta Naturae       Date:  2013-04       Impact factor: 1.845

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.